公开(公告)号：US20140086917A1

公开(公告)日：2014-03-27

申请号：US14118243

申请日：2012-05-16

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michael Sela ,  Yosef Yarden ,  Bilha Schechter ,  Ruth Maron

IPC: A61K39/395 ,  A61N5/10

CPC classification number: A61K39/39558 ,  A61K2039/505 ,  A61K2039/507 ,  A61N5/10 ,  C07K16/2863 ,  C07K16/32

Abstract: An article-of-manufacture is provided. The article-of-manufacture comprises a packaging material identified for treating cancer, packaging: (i) an anti-EGFR antibody comprising the CDR sequences of anti EGFR 565 (CNCM Deposit Number I-4262); and (ii) an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L431 (CNCM Deposit Number I-4115), anti ErbB-2 L26 (CNCM Deposit Number I-4113) or anti ErbB-2 N12 (CNCM Deposit Number I-4112), or (iii) an anti-EGFR antibody comprising the CDR sequences of anti EGFR 111 (CNCM Deposit Number I-4261); and (iv) an anti-ErbB-2 antibody comprising the CDR sequences of anti ErbB-2 L431 (CNCM Deposit Number I-4115). Also provided are pharmaceutical compositions and methods of using the above antibodies as well as other antibody combinations for the treatment of cancer.

Abstract translation: 提供制造品。 制品包括被鉴定用于治疗癌症的包装材料，包装：（i）包含抗EGFR 565（CNCM保藏号I-4262）的CDR序列的抗EGFR抗体; 和（ii）抗ErbB-2抗体，其包含抗ErbB-2 L431（CNCM保藏号I-4115），抗ErbB-2 L26（CNCM保藏号I-4113）或抗ErbB-2 N12 CNCM保藏号I-4112），或（iii）包含抗EGFR 111（CNCM存放号I-4261）的CDR序列的抗EGFR抗体; 和（iv）包含抗ErbB-2 L431（CNCM保藏号I-4115）的CDR序列的抗ErbB-2抗体。 还提供了药物组合物和使用上述抗体以及用于治疗癌症的其它抗体组合的方法。

公开(公告)号：US09358288B2

公开(公告)日：2016-06-07

申请号：US14536754

申请日：2014-11-10

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Michael Sela ,  Yosef Yarden ,  Bilha Schechter ,  Tsipi Ben-Kasus

IPC: C07K16/32 ,  A61K39/395 ,  A61K39/00

CPC classification number: A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/32 ,  C07K2317/565

Abstract: A method of identifying a combination of antibodies with a combined improved anti-tumor activity is provided. The method comprising: (a) identifying binding epitopes of anti ErbB-2 antibodies; and (b) selecting a combination of at least two antibodies of the anti ErbB-2 antibodies exhibiting binding to different epitopes on the ErbB-2, at least one of the different epitopes being localized to a dimerization site of the ErbB-2, the combination of antibodies being with the combined improved anti-tumor activity. Also provided are novel antibody combinations uncovered according to the present teachings.

Abstract translation: 提供了鉴定具有组合改善的抗肿瘤活性的抗体组合的方法。 该方法包括：（a）鉴定抗ErbB-2抗体的结合表位; 和（b）选择表现出与ErbB-2上不同表位结合的抗ErbB-2抗体的至少两种抗体的组合，至少一种不同表位位于ErbB-2的二聚位点， 抗体与组合的改善的抗肿瘤活性的组合。 还提供了根据本发明揭示的新型抗体组合。

公开(公告)号：US09926564B2

公开(公告)日：2018-03-27

申请号：US14439248

申请日：2013-10-27

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef Yarden ,  Michael Sela ,  Georg Mahlknecht ,  Ruth Maron ,  Bilha Schechter

IPC: C07H21/02 ,  C07H21/04 ,  C12N15/115 ,  A61K31/7088 ,  G01N33/574 ,  C12N5/00

CPC classification number: C12N15/115 ,  A61K31/7088 ,  C12N2310/16 ,  C12N2310/351 ,  C12N2310/3517 ,  C12N2310/51 ,  C12N2320/13 ,  C12N2320/30 ,  C12N2330/30 ,  G01N33/57492 ,  G01N2333/91205

Abstract: Monomeric and multimeric aptamers are provided. Also provided are pharmaceutical compositions which comprise same and methods of using same.

公开(公告)号：US20150266970A1

公开(公告)日：2015-09-24

申请号：US14437247

申请日：2013-10-17

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef Yarden ,  Michael Sela ,  Ruth Maron ,  Daniela Aleida Ferraro

IPC: C07K16/32 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28

CPC classification number: C07K16/32 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/507 ,  C07K16/2863 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77

Abstract: A method of treating triple negative breast cancer in a subject comprising administering to the subject a therapeutically effective amount of a combination of at least two anti epidermal growth factor receptor (EGF-R) antibodies exhibiting binding to different epitopes on the EGF-R, thereby treating triple negative breast cancer.

Abstract translation: 一种治疗受试者中的三阴性乳腺癌的方法，其包括向所述受试者施用治疗有效量的至少两种抗EGF-R抗体表皮生长因子受体（EGF-R）抗体与EGF-R上的不同表位结合的组合，从而 治疗三阴性乳腺癌。